Lyphe group
Lyphe Group is a UK-based medical cannabis care platform operating Lyphe Clinic (specialist telehealth consultations) and Lyphe Dispensary (e-commerce pharmacy) for individual patients across chronic pain, psychiatric, neurological, women's health, veterans, and palliative conditions, monetized via subscriptions and pay-as-you-go appointments, and now owned by Tilray Brands.
- Company typePrivate
- Founded2018
- HeadquartersLondon, United Kingdom
- Headcount11–50
- GTM typeB2C
- OfferingServices
What Lyphe group does
Lyphe Group is a UK-based medical cannabis care platform founded in 2018 and headquartered in Farnborough, operating primarily through its Lyphe Clinic and Lyphe Dispensary brands. The company delivers specialist clinician consultations via video and in-person channels, prescription management, and direct-to-patient dispensing across the UK and Channel Islands. Its technology stack is a conventional digital healthcare ecosystem: an eligibility checker, online appointment booking via patientbooking.co.uk, video consultations, and an integrated e-commerce pharmacy (lyphedispensary.com) that handles repeat prescriptions with free shipping.
The company monetizes through a tiered pricing model: Lyphe Saver subscriptions at £9.99/month or £99.99/year bundle consultations, repeat prescriptions, free annual medication reviews, priority clinic transfers, and shipping, advertised as 78–81% cheaper than pay-as-you-go. Pay-as-you-go appointments start at £49 per consultation, and prescription fees flow through Lyphe Dispensary. Patient acquisition is product-led (free eligibility checker, free callback booking, free clinic transfer programme) and supplemented by content marketing, earned media, industry events, and a Cancard marketing partnership. The customer base spans seven condition segments — chronic pain, psychiatric, neurological, gastrointestinal, women's health, palliative, and veterans — served entirely on a DTC individual-patient basis with no disclosed B2B customers.
Following the May 2022 £5M Series A led by Leafy Tunnel, Lyphe acquired European cannabis producer and distributor Materia in September 2022 (projected combined 2023 revenue of £23M), launched the Lyphe for Veterans access scheme in late 2025, and was itself acquired by Tilray Brands in April 2026. Under Tilray Medical ownership, Lyphe now operates as part of a vertically integrated UK medical cannabis platform spanning clinical care, dispensing, and pharmaceutical distribution, with Gro-Vida supplying UK-grown medical cannabis and Tilray providing cross-European distribution reach. The company employs 11–50 people and continues to operate its Clinic and Dispensary services as a Tilray subsidiary.
Lyphe group firmographics
Firmographics- Name
- Lyphe group
- Legal name
- Lyphe Clinic Ltd
- Website
- https://LYPHEGROUP.com
- Company type
- Private
- Founded year
- 2018
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- Lyphe Group is a UK-based medical cannabis care platform operating Lyphe Clinic (specialist telehealth consultations) and Lyphe Dispensary (e-commerce pharmacy) for individual patients across chronic pain, psychiatric, neurological, women's health, veterans, and palliative conditions, monetized via subscriptions and pay-as-you-go appointments, and now owned by Tilray Brands.
- Ownership category
- akta.pro rank
Lyphe group industry classification
Industry- Product category
- Medical Cannabis Treatment
- NAICS
- Offices of Physicians, Mental Health Specialists (621112)
- SIC
- Retail-Drug Stores And Proprietary Stores (5912), Services-Offices & Clinics Of Doctors Of Medicine (8011)
- akta.pro primary industry
- Cannabis Dispensary + Pharmacy/Clinical Model (Patient Services) (CRANAFAI)
- akta.pro secondary industries
- Medical Cannabis Dispensaries (CRANAFAB), Cannabis Subscription & Membership Delivery Programs (CRANAGAI), Cannabis Dispensary + Delivery/Online Pickup (Omnichannel Retail) (CRANAFAG)
Keywords
Where Lyphe group is headquartered
LocationHeadquarters
- HQ city
- London
- HQ country
- United Kingdom
- HQ region
- Europe
Offices1 record
Markets served
Lyphe group business model
Business model- GTM type
- B2C
- Offering type
- Services
- Cost components
- Personnel, Operations, Technology or R&D, Marketing or Sales, Supply Chain
Revenue model
- Subscription Plans: Monthly (£9.99) and annual (£99.99) subscription programmes covering initial consultations, routine appointments, repeat prescriptions, and free medication shipping
- Pay-As-You-Go Appointments: Flexible pay-per-appointment model starting from £49 per consultation for patients preferring not to commit to subscriptions
- Prescription Fees: Revenue generated from medical cannabis prescriptions fulfilled through Lyphe Dispensary with free shipping for subscribers
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Subscription | Annual | Lyphe Saver Annual - Best value subscription at £99.99 per year |
| Subscription | Monthly | Lyphe Saver Monthly - Flexible subscription at £9.99 per month |
| Other | Pay-as-you-go | Pay-As-You-Go Flexi - Per appointment pricing from £49 |
Go-to-market motion3 records
Distribution channels4 records
Marketing channels6 records
Lyphe group product offering
Product offeringCore offering
Lyphe Group operates a UK medical cannabis care platform anchored by Lyphe Clinic, providing specialist clinician consultations (online and in-person), eligibility assessments, and personalised treatment plans. The platform is integrated with Lyphe Dispensary for e-commerce prescription fulfillment and home delivery across the UK and Channel Islands. The company also runs targeted programmes such as Lyphe for Veterans and a Free Clinic Transfer scheme to broaden patient access.
Product overview
Lyphe Group operates a multi-component medical cannabis platform anchored by Lyphe Clinic, a UK-based specialist telehealth service offering online consultations, eligibility assessment, and prescription management for medical cannabis patients. The platform is complemented by Lyphe Dispensary for prescription fulfillment and home delivery, Lyphe Saver subscription plans for ongoing care, and targeted programmes such as the Free Clinic Transfer and Lyphe for Veterans scheme. The company has pursued vertical integration through the 2022 acquisition of Materia (European cannabis producer/distributor) and was itself acquired by Tilray Brands in April 2026, creating a unified platform spanning clinical care, dispensing, and pharmaceutical distribution.
Differentiator
Problem solved
Functional benefit
Products and services
- Lyphe Clinic UK-based medical cannabis clinic platform offering specialist clinician consultations (video or in-person), eligibility assessment, prescription management, and repeat prescription services, with medication delivered to patients' doors across the UK and Channel Islands.
- Lyphe Dispensary Online dispensing platform integrated with Lyphe Clinic for ordering and delivering repeat medical cannabis prescriptions to patients across the UK, with free shipping for subscribers.
- Free Clinic Transfer Priority transfer programme allowing existing patients at other UK medical cannabis clinics to move to Lyphe Clinic with streamlined onboarding and priority scheduling.
- Lyphe for Veterans Dedicated access scheme for UK military veterans aged 18+ providing medical cannabis treatment including initial consultations, follow-up appointments, and prescription delivery, covering consultation and delivery costs.
Quantifiable outcome
- 81% cheaper than pay-as-you-go plan over one year with annual subscription
- +3 more outcomes
Companies that use Lyphe group
Customer profileNamed customers3 records
Segments7 records
Ideal customer profiles3 records
Lyphe group technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature4 records
Lyphe group partnerships and signals
Strategic signalPartnerships
Four partnerships are on record, tiered core and minor.
- Tilray BrandscoreTilray Brands acquired Lyphe Group in April 2026, establishing a vertically integrated UK medical cannabis platform spanning clinical care, dispensing, and pharmaceutical distribution. Lyphe operates as a subsidiary of Tilray Medical division.
- MateriacoreEuropean medical cannabis producer and distributor acquired by Lyphe Group to create an integrated supply chain with expanded capacities and market access across Europe. Projected combined revenue of £23 million for 2023.
- Gro-VidacoreGrowing partner providing consistent UK medical cannabis supply to Lyphe Clinic patients. This unique relationship ensures continuous medication availability for patients through the subscription programme.
- CancardminorCollaboration between Cancard and Lyphe Clinic to support medical cannabis patients and promote access to legal treatment options in the UK.
Scale indicators5 records
Recent moves6 records
Expansion highlights5 records
Lyphe group competitors and assessment
Company assessmentDirect peers
- Mamedica: UK private medical cannabis clinic offering specialist consultations, prescriptions and pharmacy dispensing for chronic pain, psychiatric and neurological conditions. Directly comparable to Lyphe Clinic on patient profile, telehealth-led delivery model and condition mix.
- Sapphire Medical Clinics: One of the first UK-registered medical cannabis clinics, providing specialist consultations and prescriptions for chronic pain, psychiatry and neurology patients via a similar telehealth-led model. Sapphire is the most direct head-to-head competitor to Lyphe Clinic in the UK private cannabis clinic category.
- Alternaleaf: UK medical cannabis clinic offering online specialist consultations, prescriptions and pharmacy dispensing with a similar telehealth and subscription-oriented model. Targets overlapping chronic-pain and mental-health patient segments as Lyphe.
- Zerenia Clinics UK: UK medical cannabis clinic launched by the EMMAC/Valencian group, providing specialist consultations and prescriptions for chronic pain, psychiatry and women's health indications. Competes with Lyphe Clinic on the same UK patient base and prescribing-clinician model.
Broad incumbents
- Curaleaf International: Global medical cannabis operator with UK clinical and distribution operations (formerly Sapphire Clinics under Curaleaf). Competes with Lyphe in the UK clinic market and offers broader European cultivation and distribution capability analogous to Tilray's role as Lyphe's parent.
- Aurora Cannabis: Global medical cannabis producer with established EU-GMP cultivation and distribution in Germany and other European medical markets. Comparable to Tilray/Materia at the upstream supply side that Lyphe is now integrated into, and a relevant benchmark for European medical cannabis expansion.
- IPS Pharma: UK-specialist pharmaceutical distributor with a dedicated medical cannabis business unit supplying UK clinics and pharmacies. Directly comparable to Lyphe Dispensary's fulfillment function and represents the alternative distribution pathway Lyphe's vertical integration aims to bypass.
- Grow Pharma: UK-based medical cannabis distributor and medicines importer supplying several UK clinics including (historically) Lyphe peers. Comparable as the upstream wholesale channel that UK clinics depend on; relevant to Lyphe as both a potential partner and a competitor for vertically integrated margin.
- Canopy Growth (medical / Storz & Bickel): Global cannabis operator with European medical cannabis distribution including German medical and UK-adjacent channels. Comparable as a broad incumbent with cultivation-to-clinic vertical integration that competes with the Lyphe/Tilray platform in European medical markets.
- Tilray Brands (Medical division): Lyphe's parent company following the April 2026 acquisition; operates Tilray Medical across Canada, Europe and Australia with EU-GMP cultivation and a multi-country clinic footprint. The relevant comparable for the combined Lyphe/Tilray UK platform versus other global medical cannabis majors.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat4 records
Key risks6 records
Key highlights6 records
Customer concentration
Lyphe group social profiles
Digital presenceLyphe group financial estimates
Financial estimateRevenue estimate
Valuation estimate
Lyphe group leadership team
Management profileNumber of profiles
Profiles2 records
Lyphe group subsidiaries and ownership
Company hierarchySubsidiaries1 record
Lyphe group funding detail
Funding detailFunding overview
Funding rounds1 record
Investors2 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Lyphe group M&A and investment
M&A and investmentM&A1 record
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Lyphe group
What does Lyphe group do?
Lyphe Group operates a UK medical cannabis care platform anchored by Lyphe Clinic, providing specialist clinician consultations (online and in-person), eligibility assessments, and personalised treatment plans. The platform is integrated with Lyphe Dispensary for e-commerce prescription fulfillment and home delivery across the UK and Channel Islands. The company also runs targeted programmes such as Lyphe for Veterans and a Free Clinic Transfer scheme to broaden patient access.
Is Lyphe group a public or private company?
Lyphe group is a private company. It is classified as corporate owned and is currently operating.
When was Lyphe group founded?
Lyphe group was founded in 2018. It employs 11 to 50 people.
Where is Lyphe group based?
Lyphe group is headquartered in London, United Kingdom, in the Europe region.
How does Lyphe group make money?
Three revenue lines are on record. Subscription Plans are the primary driver. The others are pay-As-You-Go Appointments and prescription Fees.
Who are Lyphe group's main competitors?
Direct peers on record are Mamedica, Sapphire Medical Clinics, Alternaleaf and Zerenia Clinics UK. Broad incumbents are Curaleaf International, Aurora Cannabis, IPS Pharma, Grow Pharma, Canopy Growth (medical / Storz & Bickel) and Tilray Brands (Medical division).
Does Lyphe group have an API?
No public API is recorded for Lyphe group.
What industry is Lyphe group in?
Lyphe group's product category is Medical Cannabis Treatment. Its primary akta.pro industry code is CRANAFAI, Cannabis Dispensary + Pharmacy/Clinical Model (Patient Services), with a secondary code of CRANAFAB, Medical Cannabis Dispensaries. Its NAICS code is 621112 and its SIC code is 5912.